Medifron DBT Co. Ltd (065650) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Medifron DBT Co. Ltd (065650) has a cash flow conversion efficiency ratio of -0.472x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-12.73 Billion ≈ $-8.63 Million USD) by net assets (₩27.00 Billion ≈ $18.30 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Medifron DBT Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how Medifron DBT Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Medifron DBT Co. Ltd debt and liabilities for a breakdown of total debt and financial obligations.
Medifron DBT Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Medifron DBT Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NexgenRX Inc.
V:NXG
|
0.106x |
|
Prajay Engineers Syndicate Limited
NSE:PRAENG
|
0.052x |
|
Javelin Minerals Ltd
AU:JAV
|
-0.059x |
|
Genus PLC
LSE:GNS
|
0.100x |
|
RONSHINE CH.HLD.HD-00001
F:1R7
|
N/A |
|
MK Trend Co. Ltd.
KO:069640
|
-0.361x |
|
CLEAN TEQ WATER LTD
F:9NK
|
N/A |
|
Argha Karya Prima Ind Tbk
JK:AKPI
|
0.033x |
Annual Cash Flow Conversion Efficiency for Medifron DBT Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of Medifron DBT Co. Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Medifron DBT Co. Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩17.49 Billion ≈ $11.85 Million |
₩-4.54 Billion ≈ $-3.07 Million |
-0.259x | -347.44% |
| 2023-12-31 | ₩36.89 Billion ≈ $25.00 Million |
₩-2.14 Billion ≈ $-1.45 Million |
-0.058x | +38.16% |
| 2022-12-31 | ₩31.09 Billion ≈ $21.07 Million |
₩-2.91 Billion ≈ $-1.97 Million |
-0.094x | -163.79% |
| 2021-12-31 | ₩42.29 Billion ≈ $28.66 Million |
₩-1.50 Billion ≈ $-1.02 Million |
-0.036x | +40.87% |
| 2020-12-31 | ₩27.86 Billion ≈ $18.88 Million |
₩-1.67 Billion ≈ $-1.13 Million |
-0.060x | +75.19% |
| 2019-12-31 | ₩17.69 Billion ≈ $11.99 Million |
₩-4.28 Billion ≈ $-2.90 Million |
-0.242x | -445.39% |
| 2018-12-31 | ₩19.20 Billion ≈ $13.01 Million |
₩-852.48 Million ≈ $-577.71K |
-0.044x | +6.08% |
| 2017-12-31 | ₩24.75 Billion ≈ $16.77 Million |
₩-1.17 Billion ≈ $-793.09K |
-0.047x | -4.98% |
| 2016-12-31 | ₩25.57 Billion ≈ $17.33 Million |
₩-1.15 Billion ≈ $-780.62K |
-0.045x | -529.58% |
| 2015-12-31 | ₩23.80 Billion ≈ $16.13 Million |
₩-170.27 Million ≈ $-115.39K |
-0.007x | -25520.44% |
| 2014-12-31 | ₩24.94 Billion ≈ $16.90 Million |
₩701.96K ≈ $475.71 |
0.000x | -- |
About Medifron DBT Co. Ltd
Hyper Corporation Inc., a clinical stage biopharmaceutical company, focuses on the development of Alzheimer's disease (AD) and neuropathic pain treatments, and AD diagnostics. Its products under development include TRPV1 Antagonist and TRPV1 Agonist for neuropathic pain; and anti-oligomerization of beta-amyloid, receptor for advanced glycation endproduct modulator, and early diagnosis kits for AD… Read more